Once-daily treatment with pitolisant is generally safe and helps reduce excessive daytime sleepiness (EDS) and abnormal behaviors in people with…
Articles by Margarida Maia, PhD
Hypogonadism, a condition in which the body produces few or no sex hormones, is common in girls and young women…
Aardvark Therapeutics plans to expand its ongoing Phase 3 clinical trial of ARD-101, an oral therapy for easing excessive…
A year of treatment with somatropin safely maintains or improves body composition in Japanese children and adults with Prader-Willi…
Most children and adolescents with Prader-Willi syndrome (PWS) experience frequent anxiety and engage in distress-related behaviors that become a…
Vykat XR (diazoxide choline) can safely reduce hyperphagia — a feeling of insatiable hunger that is a hallmark of…
After discontinuing Vykat XR (diazoxide choline) for a few months as part of a clinical trial, Prader-Willi syndrome…
Thanks to strong enrollment in a Phase 3 clinical trial of Acadia Pharmaceuticals’ ACP-101 — an experimental nasal spray…
The first eligible Prader-Willi syndrome (PWS) patients in the U.S. have received their prescriptions for Vykat XR (diazoxide…
The U.S. Food and Drug Administration (FDA) has approved Soleno Therapeutics’ extended-release formulation of diazoxide choline (DCCR) for easing…